Novel immunotherapeutic approaches in targeting dendritic cells with virus vectors

Discovery Medicine

Volumn 20, Issue 109, 2015, Pages 111-119

  Pereira, Bruna de Andrade ^a   Fraefel, Cornel ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ADENOVIRUS VECTOR; ANTIGEN; CAPSID PROTEIN; CD14 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA RETROVIRUS VECTOR; IMMUNOGLOBULIN G; INTERLEUKIN 10; LECTIN RECEPTOR; MEMBRANE PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; NONSTRUCTURAL PROTEIN 3; NUCLEIC ACID; OVALBUMIN; PATTERN RECOGNITION RECEPTOR; RETROVIRUS VECTOR; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CELL ADHESION; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOUBLE-STRANDED DNA VIRUS; GENE THERAPY; GENE TRANSFER; HEPATITIS C VIRUS; HERPESVIRIDAE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LENTIVIRINAE; LYMPH NODE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POXVIRIDAE; SEVERE COMBINED IMMUNODEFICIENCY; SUICIDE GENE; TUMOR CELL; VIRUS INFECTION; ADENOVIRIDAE; ANIMAL; BONE MARROW CELL; CLINICAL TRIAL (TOPIC); CYTOLOGY; DEPENDOPARVOVIRUS; GENE VECTOR; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; PROCEDURES; RETROVIRIDAE; TRANSGENE;

ADENOSINE DEAMINASE; ADENOVIRIDAE; ANIMALS; BONE MARROW CELLS; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HERPESVIRIDAE; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOTHERAPY; LENTIVIRUS; POXVIRIDAE; RETROVIRIDAE; TRANSGENES;

EID: 84944459106     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC, Bosticardo M, Evangelio C, Assanelli A, Casiraghi M, Di Nunzio S, Callegaro L, Benati C, Rizzardi P, Pellin D, Di Serio C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341(6148):1233151, 2013.
2. de Andrade Pereira B, Fraefel C, Hilbe M, Ackermann M, Dresch C. Transcriptional targeting of DCs with lentiviral vectors induces antigen-specific tolerance in a mouse model of multiple sclerosis. Gene Ther 20(5):556-566, 2013.
3. de Andrade Pereira B, Ackermann M, Chaudhary S, Vogel R, Vogt B, Dresch C, Fraefel C. Tolerance of activated pathogenic CD4+ T cells by transcriptional targeting of dendritic cells. Gene Ther 22(5):382-390, 2015.
4. Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. Targeting Antigens to Dendritic Cell Receptors for Vaccine Development. Journal of Drug Delivery 2013(4):1-22, 2013.
5. Badovinac VP, Messingham KAN, Jabbari A, Haring JS, Harty JT. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 11(7):748-756, 2005.
6. BiffiA, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NAL, Cicalese MP, Casiraghi M, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341(6148):1233158, 2013.
7. Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, AtefiM, Kroeger N, Chandramouli GVR, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM.CAIX in immunocompetent mouse models. J Immunother 36(2):102-111, 2013.
8. Breckpot K, Emeagi P, Dullaers M, Michiels A, Heirman C, Thielemans K. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum Gene Ther 18(6):536-546, 2007.
9. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 158(7):3270-3276, 1997.
10. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang J, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 31(3):294-309, 2008.
11. Chan J, Ban EJ, Chun KH, Wang S, Bäckström BT, Bernard CCA, Toh B, Alderuccio F. Transplantation of bone marrow transduced to express self-antigen establishes deletional tolerance and permanently remits autoimmune disease. J Immunol 181(11):7571-7580, 2008.
12. Chia WK, Wang W, Teo M, Tai WM, Lim WT, Tan EH, Leong SS, Sun L, Chen JJ, Gottschalk S, Toh HC. A phase II study evaluating the safety and efficacy of an adenovirus-LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol 23(4):997-1005, 2012.
13. Dakappagari N, Maruyama T, Renshaw M, Tacken P, Figdor C, Torensma R, Wild MA, Wu D, Bowdish K, Kretz-Rommel A. Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses. J Immunol 176(1):426-440, 2006.
14. den Haan JM, Lehar SM, Bevan MJ. CD8 (+) but not CD8 (-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 192(12):1685-1696, 2000.
15. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193(2):233-238, 2001.
16. Dillman RO, Cornforth AN, Depriest C, McClay EF, Amatruda TT, Leon C de, Ellis RE, Mayorga C, Carbonell D, Cubellis JM. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother 35(8):641-649, 2012.
17. Dullaers M, van Meirvenne S, Heirman C, Straetman L, Bonehill A, Aerts JL, Thielemans K, Breckpot K. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 13(7):630-640, 2006.
18. Eixarch H, Espejo C, Gómez A, Mansilla MJ, Castillo M, Mildner A, Vidal F, Gimeno R, Prinz M, Montalban X, Barquinero J. Tolerance induction in experimental autoimmune encephalomyelitis using non-myeloablative hematopoietic gene therapy with autoantigen. Mol Ther 17(5):897-905, 2009.
19. Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Lévy F, MacDonald HR. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8 (+) T cell responses. J Clin Invest 111(11):1673-1681, 2003.
20. Flacher V, Tripp CH, Haid B, Kissenpfennig A, Malissen B, Stoitzner P, Idoyaga J, Romani N. Skin langerin+ dendritic cells transport intradermally injected anti-DEC-205 antibodies but are not essential for subsequent cytotoxic CD8+ T cell responses. J Immunol 188(5):2146-2155, 2012.
21. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, Figdor CG. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100(5):575-585, 2000.
22. Gennari F, Lopes L, Verhoeyen E, Marasco W, Collins MK. Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells. Human Gene Ther 20(6):554-562, 2009.
23. Gruber A, Kan-Mitchell J, Kuhen KL, Mukai T, Wong-Staal F. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood 96(4):1327-1333, 2000.
24. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH, Leiva L, Sorensen R, Debré M, Casanova JL, Blanche S, Durandy A, Bushman FD, Fischer A, Cavazzana-Calvo M. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363(4):355-364, 2010.
25. Heath WR, Belz GT, Behrens GMN, Smith CM, Forehan SP, Parish IA, Davey GM, Wilson NS, Carbone FR, Villadangos JA. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199:9-26, 2004.
26. Henry E, Desmet CJ, Garzé V, Fiévez L, Bedoret D, Heirman C, Faisca P, Jaspar FJ, Gosset P, Jacquet APA, Desmecht D, Thielemans K, Lekeux P, Moser M, Bureau F. Dendritic cells genetically engineered to express IL-10 induce long-lasting antigen-specific tolerance in experimental asthma. J Immunol 181(10):7230-7242, 2008.
27. Hira SK, Mondal I, Manna PP. Combined immunotherapy with whole tumor lysate-pulsed interleukin-15-activated dendritic cells and cucurbitacin I promotes strong CD8+ T-cell responses and cures highly aggressive lymphoma. Cytotherapy 17(5):647-664, 2015.
28. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, Ridder D de, Gilmour KC, Adams S, Thornhill SI, Parsley KL, Staal FJ, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118(9):3143-3150, 2008.
29. Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, Huang Y, Rodriguez A, Clausen BE, Park CG, Trumpfheller C, Steinman RM. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci U S A 108(6):2384-2389, 2011.
30. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 22(2):102-107, 2001.
31. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 12(8):557-569, 2012.
32. KantoffPW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411-422, 2010a.
33. KantoffPW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28(7):1099-1105, 2010b.
34. Ko H, Chung J, Nasa Z, Chan J, Siatskas C, Toh B, Alderuccio F. Targeting MOG expression to dendritic cells delays onset of experimental autoimmune disease. Autoimmunity 44(3):177-187, 2011.
35. Larsen CP, Ritchie SC, Pearson TC, Linsley PS, Lowry RP. Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations. J Exp Med 176(4):1215-1220, 1992.
36. Lopes L, Dewannieux M, Gileadi U, Bailey R, Ikeda Y, Whittaker C, Collin MP, Cerundolo V, Tomihari M, Ariizumi K, Collins MK. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol 82(1):86-95, 2008.
37. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 14(1):129-135, 2002.
38. Metcalfe W, Anderson J, Trinh V, Hwu W. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma. Discov Med 19(106):393-401, 2015.
39. Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 72(10):8150-8157, 1998.
40. Nakano H, Lin KL, Yanagita M, Charbonneau C, Cook DN, Kakiuchi T, Gunn MD. Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses. Nat Immunol 10(4):394-402, 2009.
41. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259):263-267, 1996.
42. Negre O, Fusil F, Colomb C, Roth S, Gillet-Legrand B, Henri A, Beuzard Y, Bushman F, Leboulch P, Payen E. Correction of murine-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion. Blood 117(20):5321-5331, 2011.
43. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328-332, 1998.
44. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12(4):265-277, 2012.
45. Pincha M, Salguero G, Wedekind D, Sundarasetty BS, Lin A, Kasahara N, Brugman MH, Jirmo AC, Modlich U, Gutzmer R, Büsche G, Ganser A, Stripecke R. Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells. Gene Ther 18(8):750-764, 2011.
46. Pincha M, Sai Sundarasetty B, Salguero G, Gutzmer R, Garritsen H, Macke L, Schneider A, Lenz D, Figueiredo C, Blasczyk R, Ruggiero E, Schmidt M, Kalle C, von PuffC, Modlich U, Leyen H, von der Wicke DC, Ganser A, Stripecke R. Identity, potency, in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapy. Hum Gene Ther Methods 23(1):38-55, 2012.
47. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296, 2007.
48. Ramezani A, Hawley RG. Strategies to insulate lentiviral vector-expressed transgenes. Methods Mol Biol 614:77-100, 2010.
49. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 5(8):617-628, 2005.
50. Rossetti M, Gregori S, Hauben E, Brown BD, Sergi LS, Naldini L, Roncarolo M. HIV-1-derived lentiviral vectors directly activate plasmacytoid dendritic cells, which in turn induce the maturation of myeloid dendritic cells. Hum Gene Ther 22(2):177-188, 2011.
51. Scheeren RA, Koopman G, van der Baan S, Meijer CJ, Pals ST. Adhesion receptors involved in clustering of blood dendritic cells and T lymphocytes. Eur J Immunol 21(5):1101-1105, 1991.
52. Schröder ARW, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110(4):521-529, 2002.
53. Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, Butterfield LH. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 27(3):191-200, 2004.
54. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Devel 25(24):2559-2572, 2011.
55. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal RG. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 186(8):1247-1256, 1997.
56. Stoitzner P, Schaffenrath S, Tripp CH, Reider D, Komenda K, Del Frari B, Djedovic G, Ebner S, Romani N. Human skin dendritic cells can be targeted in situ by intradermal injection of antibodies against lectin receptors. Exp Dermatol 23(12):909-915, 2014.
57. Sumida K, Shimoda S, Iwasaka S, Hisamoto S, Kawanaka H, Akahoshi T, Ikegami T, Shirabe K, Shimono N, Maehara Y, Selmi C, Gershwin ME, Akashi K. Characteristics of splenic CD8 + T cell exhaustion in patients with hepatitis C. Clin Exp Immunol 174(1):172-178, 2013.
58. Tenbusch M, Nchinda G, Storcksdieck G, Bonsmann M, Temchura V, Uberla K. Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response. Int Immunol 25(4):247-258, 2013.
59. Toscano MG, Delgado M, Kong W, Martin F, Skarica M, Ganea D. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther 18(5):1035-1045, 2010.
60. Wang X, Bayer ME, Chen X, Fredrickson C, Cornforth AN, Liang G, Cannon J, He J, Fu Q, Liu J, Nistor GI, Cao W, Chen C, Dillman RO. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol 111(7):862-867, 2015.
61. Woods N, Bottero V, Schmidt M, Kalle C, von Verma IM. Gene therapy: therapeutic gene causing lymphoma. Nature 440(7088):1123, 2006.
62. Xu B, Haviernik P, Wolfraim LA, Bunting KD, Scott DW. Bone marrow transplantation combined with gene therapy to induce antigen-specific tolerance and ameliorate EAE. Mol Ther 13(1):42-48, 2006.
63. Yang L, Yang H, Rideout K, Cho T, Joo KI, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D, Wang P. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 26(3):326-334, 2008.
64. Young JW, Koulova L, Soergel SA, Clark EA, Steinman RM, Dupont B. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest 90(1):229-237, 1992.
65. Zabaleta A, D'Avola D, Echeverria I, Llopiz D, Silva L, Villanueva L, Riezu-Boj JI, Larrea E, Pereboev A, Lasarte JJ, Rodriguez-Lago I, Iñarrairaegui M, Sangro B, Prieto J, Sarobe P. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. Mol Ther Methods Clin Dev 2:15006, 2015.